Skip to main content
Caplight Logo









ALP Bio AG

ALP Bio AG

Private
SchlierenHealthcare & Life Scienceshttps://alp.bio/

Last Round

Grant

Jul 3, 2026

Total Funding Raised

$2.39M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

ALP Bio AG is a biotechnology company developing an immune organoid and AI platform for immunogenicity intelligence in biologics development.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Medical AI, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting, Revenue Share, Subscription SaaS

AI Layer

Application

Keywords

immunogenicity predictionimmunogenicity risk assessmentanti-drug antibody riskADA riskhuman immune organoidsAI drug discoverydrug de-riskinggenerative AItonsil organoidsorganoid platformcomputational immunologybiobetter designantibody engineeringin silico screeningex vivo validationantibody therapeuticslab-in-the-loopprotein language models

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

ALP Bio AG Comparables

Compare ALP Bio AG with similar companies based on industry and business-model similarity.

ALP Bio AG comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
EpiVax
76%
ProImmune Ltd
74%
Parallel Bio
71%

ALP Bio AG Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantJul 3, 2026
Pre SeedApr 30, 2026

ALP Bio AG Investors

Notable investors and investment history

ALP Bio AG investors
InvestorRounds
42CAPPre Seed
Venture KickGrant, Pre Seed
Ajira VenturesPre Seed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 3, 2026

    $187K grant received from Venture Kick.

  • Apr 30, 2026

    $2.2M round led by 42CAP.

Recent news

Latest coverage and updates

  • is_developingSep 28, 2026

    Alp Bio AG is developing immunogenicity-intelligence platform for biologic drugs.

  • is_developingJul 3, 2026

    Alp Bio AG is developing AI-powered platform.

  • receives_financingJul 3, 2026

    Alp Bio AG received financing of $184K in Seed on Jul 3rd '26.

ALP Bio AG Filings

Explore SEC and related filing metadata, where available.

ALP Bio AG filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about ALP Bio AG's valuation, stock price, and market status.

Is ALP Bio AG a public or private company?

ALP Bio AG is a private company.

What is the current stock price of ALP Bio AG?

ALP Bio AG is a private company with no public stock price. No recent secondary market data is available.

How much is ALP Bio AG worth (valuation)?

Valuation information for ALP Bio AG is not publicly available.

Can I buy ALP Bio AG stock?

ALP Bio AG shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was ALP Bio AG's last funding round?

ALP Bio AG's most recent funding round was Pre Seed on April 30, 2026.

Who are the main investors in ALP Bio AG?

Key investors in ALP Bio AG include 42CAP.

Will ALP Bio AG IPO soon?

No public IPO plans have been announced for ALP Bio AG.

How can I track ALP Bio AG secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor ALP Bio AG's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersSchlieren
Year Founded2025
Last FundingJul 3, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?